Biogen Fights Aduhelm’s Medicare Blow by Boosting Lobbying Ranks

The maker of an Alzheimer’s drug and patient advocates are growing their lobbying presence as they press Medicare to reverse a move they fear will have dire consequences for patient access to the medication.

Biogen Inc. hired William Clyburn, Jr. — a relative of House Majority Whip Jim Clyburn (D-S.C.) — to lobby for the company, according to federal disclosures released this week. UsAgainstAlzheimer’s and Global Alzheimer’s Platform Innovations PBC also hired new lobbying groups at the beginning of 2022, according to the disclosures. Both groups have advocated for Medicare to expand coverage of Biogen’s drug Aduhelm after the ...